PGR and breast cancer: Among them, only 2/30 (6.7%) breast cancer patients from the phase Ib KEYNOTE-012 study completed the 2-year treatment and were of triple-negative (i.e., ER-negative, progesterone receptor (PR)-negative, and HER2-negative) phenotype [22].